Has Abdhish Bhavsar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $21,417 in general payments to Abdhish Bhavsar, MD across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Abdhish Bhavsar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Abdhish Bhavsar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Abdhish Bhavsar, MD

Retina Specialist · Minneapolis, MNNPI 1396776951

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,628 of the $21,417 with a category attached, or 91.6%. AbbVie accounts for 64.4% of it on its own, with 1 other manufacturer making up the rest. Among retina specialist clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,417in general payments, 2019–2025

Across 21 payments — averaging $1019.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$14K
Ocular Therapeutix, Inc.$8K

$71,951in research payments, 2019–2025

Across 10 payments — averaging $7195.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$54K
Astellas Pharma Global Development$12K
AstraZeneca$6K

What the payments were for

Consulting fees$19,62892%
Travel & lodging$9064%
Food & beverage$8834%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	19	$13,789
Ocular Therapeutix, Inc.	2	$7,628

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OZURDEX$143

How this compares

$21,417 in reported general payments places this provider in the 90th percentile of 20 retina specialist providers in Minnesota.

See all retina specialist providers in Minnesota →

Medicare billing

Part B allowed, 2024

$2,892,773

Medicare patients

1,003

Services billed

19,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	301	$15,600
RestasisCyclosporine	11	$6,378
LotemaxLoteprednol Etabonate	11	$3,835
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	94	$1,944
Ketorolac Tromethamine	71	$1,719
Atropine Sulfate	17	$445
Timolol Maleate	29	$368
Dorzolamide Hcl	12	$360
Brimonidine Tartrate	26	$279
Diclofenac Sodium	15	$263
Latanoprost	13	$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieRestasis	$13,789	$6,37811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 retina specialist providers in Minnesota.

Other retina specialist in Minneapolis

Geoffrey EmersonMinneapolis$500
Hossein NazariMinneapolis$377
Jacob JonesMinneapolis$164
Yevgeniy SychevMinneapolis$0
Malav JoshiRochester$293K
Zeeshan HaqEdina$12K
David WilliamsBaxter$9K
Michael MaywoodEdina$5K
Guneet SodhiEdina$3K
Sahal SalehEdina$3K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →